Coronavirus Disease 2019 Outcomes, Patient Vaccination Status, and Cancer-Related Delays During the Omicron Wave: A Brief Report From the TERAVOLT Analysis.

Détails

Ressource 1Télécharger: 35619644_BIB_EBBB31952F9C.pdf (219.32 [Ko])
Etat: Public
Version: Final published version
Licence: CC BY-NC-ND 4.0
ID Serval
serval:BIB_EBBB31952F9C
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
Coronavirus Disease 2019 Outcomes, Patient Vaccination Status, and Cancer-Related Delays During the Omicron Wave: A Brief Report From the TERAVOLT Analysis.
Périodique
JTO clinical and research reports
Auteur⸱e⸱s
Bestvina C.M., Whisenant J.G., Torri V., Cortellini A., Wakelee H., Peters S., Roca E., De Toma A., Hirsch F.R., Mamdani H., Halmos B., Arrieta O., Metivier A.C., Fidler M.J., Rogado J., Presley C.J., Mascaux C., Genova C., Blaquier J.B., Addeo A., Finocchiaro G., Khan H., Mazieres J., Morgillo F., Bar J., Aujayeb A., Mountzios G., Scotti V., Grosso F., Geraedts E., Zhumagaliyeva A.N., Horn L., Garassino M.C., Baena J.
Collaborateur⸱rice⸱s
TERAVOLT study group
ISSN
2666-3643 (Electronic)
ISSN-L
2666-3643
Statut éditorial
Publié
Date de publication
08/2022
Peer-reviewed
Oui
Volume
3
Numéro
8
Pages
100335
Langue
anglais
Notes
Publication types: Journal Article
Publication Status: ppublish
Résumé
The Thoracic Centers International coronavirus disease 2019 (COVID-19) Collaboration (TERAVOLT) registry found approximately 30% mortality in patients with thoracic malignancies during the initial COVID-19 surges. Data from South Africa suggested a decrease in severity and mortality with the Omicron wave. Our objective was to assess mortality of patients with thoracic malignancies with the Omicron-predominant wave and evaluate efficacy of vaccination.
A prospective, multicenter observational study was conducted. A total of 28 institutions contributed data from January 14, 2022, to February 4, 2022. Inclusion criteria were any thoracic cancer and a COVID-19 diagnosis on or after November 1, 2021. End points included mortality, hospitalization, symptomatic COVID-19 infection, asymptomatic COVID-19 infection, and delay in cancer therapy. Analysis was done through contingency tables and a multivariable logistic model.
We enrolled a total of 346 patients. Median age was 65 years, 52.3% were female, 74.2% were current or former smokers, 86% had NSCLC, 72% had stage IV at time of COVID-19 diagnosis, and 66% were receiving cancer therapy. Variant was unknown for 70%; for those known, Omicron represented 82%. Overall mortality was 3.2%. Using multivariate analysis, COVID-19 vaccination with booster compared with no vaccination had a protective effect on hospitalization or death (OR = 0.30, confidence interval: 0.15-0.57, p = 0.0003), whereas vaccination without booster did not (OR = 0.64, confidence interval: 0.33-1.24, p = 0.1864). Cancer care was delayed in 56.4% of the patients.
TERAVOLT found reduced patient mortality with the most recent COVID-19 surge. COVID-19 vaccination with booster improved outcomes of hospitalization or death. Delays in cancer therapy remain an issue, which has the potential to worsen cancer-related mortality.
Mots-clé
COVID-19, Cancer, NSCLC, Registry, TERAVOLT, Thoracic
Pubmed
Open Access
Oui
Création de la notice
17/06/2022 13:14
Dernière modification de la notice
25/01/2024 7:46
Données d'usage